profit from every $100 of sales.
$0$100
Galmed Pharmaceuticals
We have no price for Galmed Pharmaceuticals since 8 October 2026. It may have been taken over, merged or renamed, so the figures below are from then.
$3.62+4.69% today
+146.3% in 1 year
1-year low $0.541-year high $6.28
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Galmed Pharmaceuticals sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$10.3 million of profit last year.
SalesProfit
Galmed Pharmaceuticals vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Galmed Pharmaceuticals | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Galmed Pharmaceuticals's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -18 | -7 | -6 | -9 | |
| -18 | -7 | -6 | -9 | |
| -18 | -7 | -8 | -10 | |
| -127.80 | -30.00 | -8.08 | -2.39 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 17 | 17 | 19 | 19 |
| Cash | 2 | 3 | 5 | 4 |
| Total debt | 0 | 0 | 0 | – |
| Total liabilities | 3 | 3 | 2 | 3 |
| 13 | 14 | 16 | 16 | |
| 0 | 0 | 1 | 4 | |
| -102.2% | -42.5% | -30.4% | -42.6% | |
| -133.1% | -49.8% | -46.0% | -65.3% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -19 | -6 | -6 | -6 | |
| 0 | – | – | – | |
| -19 | -6 | -6 | -6 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 1 | 1 | 1 | 1 |
Valuation
- –
- –
- –
- 0.3×
- –
- –
- 0.1×
- -127.7%
- -208.4%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -53.9%
- -79.5%
- -57.0%
- -55.3%
- -53.9%
- –
Growth
- –
- –
- −7.4%
- –
- +27.3%
Financial health
- -0.5×
- 0.00
- 0.0%
- –
- 6.55
- 6.55
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 4%of 963
Bottom 20%of 894
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Mar 31, 2026 | -0.92 | -0.38 | −142.1% |
| Nov 26, 2025 | -0.33 | -0.54 | +38.9% |
| Aug 28, 2025 | 0.63 | -0.83 | +175.9% |
| May 22, 2025 | -0.62 | -0.89 | +30.3% |
| Apr 2, 2025 | -11.76 | – | – |
| Nov 14, 2024 | -2.31 | – | – |
| Aug 28, 2024 | 2.16 | – | – |
| May 30, 2024 | -2.76 | – | – |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
43No pass
Benjamin Graham
79Pass
Philip Fisher
31No pass
Peter Lynch
60Pass
Joel Greenblatt
50No pass
Charlie Munger
24No pass
Terry Smith
19No pass
Questions about Galmed Pharmaceuticals
Is Galmed Pharmaceuticals a good stock to buy?
A business with weak numbers that is not profitable yet. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Galmed Pharmaceuticals AI analysis
What does Galmed Pharmaceuticals do?
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It is in Biotechnology.
Does Galmed Pharmaceuticals pay a dividend?
No. Galmed Pharmaceuticals does not pay a dividend at the moment.
Is Galmed Pharmaceuticals stock halal?
No. Galmed Pharmaceuticals does not pass our halal screen: its cash and confirmed interest-bearing investments are 81% of its market value, at or above the 33% limit. How we check
How has Galmed Pharmaceuticals stock done over the past year?
Up 146.3% over the past twelve months, to $3.62. It traded between $0.54 and $6.28 and is 42.4% below its high.
Who are Galmed Pharmaceuticals's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Galmed Pharmaceuticals's.
Prices: daily closes to Oct 8, 2026. Fundamentals: company reports via invest-like data.